Bidzan Malik, Eter Nicole, Uhlig Constantin E
Department of Ophthalmology, University of Muenster Medical Center, Albert-Schweitzer-Campus 1, Building D15, 48149, Münster, Germany.
Ophthalmol Ther. 2024 Apr;13(4):979-994. doi: 10.1007/s40123-024-00889-z. Epub 2024 Feb 12.
To investigate the long-term outcomes of emergency penetrating keratoplasty using cryopreserved human donor corneas in the management of actual or imminent corneal perforation.
A retrospective analysis was performed of the treatment efficacy of emergency penetrating keratoplasty using a cryopreserved human donor cornea, in 14 eyes of 14 patients with corneal ulcers of different etiology. For comparison, the medical histories of 14 patients who had undergone penetrating keratoplasty with the same indication, but received a regularly processed human corneal graft, were retrospectively analyzed. In both groups, the primary endpoint for graft failure was repeat surgery, defined as the necessity for amniotic membrane transplantation, conjunctival flap, or repeat penetrating keratoplasty, during a follow-up time of maximally 12 months.
The difference in the need for repeated surgeries between the cryopreserved human donor cornea group and cultivated tissue graft group was not statistically significant (p = 0.835). Specifically, repeat complex surgery of any kind within 6 months was necessary in 50% of the cryopreserved cornea group and in 57.1% of the control group, with no further surgical interventions during the remainder of the follow-up period. However, repeat penetrating keratoplasty occurred more frequently in the cryopreserved cornea group (n = 5) than in the control group (n = 1) during the first 12 months after treatment (p = 0.048).
Cryopreserved corneas appear to be a viable option for promptly addressing emergencies and stabilizing the corneal situation, providing a faster solution compared to waiting for fresh tissue availability. However, repeat penetrating keratoplasty is more frequent when cryopreserved human donor corneas are used. Cryopreserved human donor corneas may be useful if surgical treatment is urgent and alternative options, such as tissue use, a conjunctival flap, or multilayer amniotic membrane transplantation, are not available.
探讨使用低温保存的人类供体角膜进行急诊穿透性角膜移植术治疗实际或即将发生的角膜穿孔的长期疗效。
对14例不同病因角膜溃疡患者的14只眼使用低温保存的人类供体角膜进行急诊穿透性角膜移植术的治疗效果进行回顾性分析。为作比较,对14例有相同适应证但接受常规处理的人类角膜移植片进行穿透性角膜移植术患者的病史进行回顾性分析。两组中,移植失败的主要终点为再次手术,定义为在最长12个月的随访期内进行羊膜移植、结膜瓣或再次穿透性角膜移植术的必要性。
低温保存的人类供体角膜组和培养组织移植组之间再次手术需求的差异无统计学意义(p = 0.835)。具体而言,低温保存角膜组50%的患者和对照组57.1%的患者在6个月内需要进行任何一种再次复杂手术,在随访期的其余时间内未进行进一步的手术干预。然而,在治疗后的前12个月内,低温保存角膜组(n = 5)再次穿透性角膜移植术的发生率高于对照组(n = 1)(p = 0.048)。
低温保存的角膜似乎是迅速处理紧急情况和稳定角膜状况的可行选择,与等待新鲜组织可用相比,提供了更快的解决方案。然而,使用低温保存的人类供体角膜时再次穿透性角膜移植术更频繁。如果手术治疗紧急且没有其他选择,如组织使用、结膜瓣或多层羊膜移植,则低温保存的人类供体角膜可能有用。